BCLS Acquisition Corp.
BLSA
NASDAQ Capital Market10.04
USD
- -
- -
BCLS Acquisition Corp.
BLSA
(NASDAQ Capital Market)
Recent
price
10.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BCLS Acquisition Corp. (BLSA) is a blank check company sponsored by an affiliate of Bain Capital Life Sciences whose shares were redeemed and delisted from Nasdaq following its liquidation in October 2022. Formed in 2020 and based in Boston, Massachusetts, the company had no significant operations or revenue; it sought to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, focusing primarily on biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies in North America and Europe, with selective opportunities in Asia and emerging markets. In October 2022, after failing to complete an initial business combination within the required timeframe, BCLS Acquisition announced the redemption of all its public Class A ordinary shares at approximately the initial offering price, ceasing trading on Nasdaq as of October 26, 2022, cancelling the shares, and winding down operations except for liquidation requirements. The company had priced its $125 million initial public offering in October 2020 at $10 per Class A share, led by Chairman Adam Koppel, CEO Jeffrey Schwartz, and CFO Andrew Hack, with Goldman Sachs and Jefferies as lead underwriters.
BCLS Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination
BCLS Acquisition Corp. Announces Pricing of $125 Million Initial Public Offering